CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2014 - 2026)
CytomX Therapeutics (CTMX) posted Other Non-Current Liabilities of $4.4 million for Q1 2026, up 1.36% on a QoQ basis from $4.4 million in Q4 2025, and up 5.63% year-over-year from $4.2 million in Q1 2025.
CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 5.63% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 5.63% YoY) and the FY2025 annual result came in at $4.4 million, up 5.78% from the prior year.
- Other Non-Current Liabilities was $4.4 million for Q1 2026 at CytomX Therapeutics, up from $4.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $4.4 million in Q1 2026 and bottomed at $216000.0 in Q2 2023.
- A 4-year average of $3.7 million and a median of $4.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 1748.61% — and 2026, when it grew 5.63%.
- CytomX Therapeutics' Other Non-Current Liabilities stood at $3.9 million in 2023, then rose by 5.7% to $4.1 million in 2024, then increased by 5.78% to $4.4 million in 2025, then climbed by 1.36% to $4.4 million in 2026.
- Business Quant data shows CTMX's Other Non-Current Liabilities at $4.4 million in Q1 2026, $4.4 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.41 Mn |
| Dec 31, 2025 | 4.35 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 4.24 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 4.05 Mn |
| Jun 30, 2024 | 3.99 Mn |
| Mar 31, 2024 | 3.94 Mn |
| Dec 31, 2023 | 3.89 Mn |
| Sep 30, 2023 | 2.76 Mn |
| Jun 30, 2023 | 216,000.00 |
| Dec 31, 2019 | 850,000.00 |
| Sep 30, 2019 | 963,000.00 |
| Jun 30, 2019 | 963,000.00 |
| Mar 31, 2019 | 963,000.00 |
| Dec 31, 2018 | 3.05 Mn |
| Sep 30, 2018 | 2.43 Mn |
| Jun 30, 2018 | 2.28 Mn |
| Mar 31, 2018 | 2.06 Mn |